Celgene logo Celgene (NASDAQ:CELG) announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.45 by $0.10, Bloomberg Earnings reports. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. Celgene updated its FY19 guidance to $10.60-10.80 EPS.
CELG stock opened at $95.21 on Friday. The company has a market capitalization of $67.27 billion, a P/E ratio of 12.51, a P/E/G ratio of 0.43 and a beta of 1.68. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42. Celgene has a 52 week low of $58.59 and a 52 week high of $95.45.
CELG has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a research report on Friday, February 1st. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. William Blair restated a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Finally, Wells Fargo & Co dropped their target price on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a research report on Thursday, January 3rd. One research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $99.13.
In other news, Director Ernest Mario bought 2,000 shares of the business’s stock in a transaction dated Tuesday, February 12th. The stock was purchased at an average cost of $89.99 per share, with a total value of $179,980.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link . Also, Director James J. Loughlin sold 23,466 shares of Celgene stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the transaction, the director now directly owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The disclosure for this sale can be found here . 0.39% of the stock is owned by company insiders.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What are the qualifications of a portfolio manager? Earnings History for Celgene (NASDAQ:CELG) Receive News & Ratings for Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Celgene (CELG) Announces Quarterly Earnings Results